Scientific articles

Advancing ATMPs for orphan diseases: redefining the roles of pharmaceutical companies and academia

9 February, 2026/by Adel Medzikovic

Reimbursement routes and past practices for advanced therapy medicinal products in the Netherlands

9 February, 2026/by Adel Medzikovic

Publication: Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe

29 September, 2025/by Adel Medzikovic

NTvH artikel ‘DARE-NL: Nederlands platform voor snellere toegang tot ATMP’s bij kanker’ (in Dutch)

2 March, 2024/by Adel Medzikovic

Article in BJCP: ‘EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells’

15 February, 2024/by Adel Medzikovic

Rapport ‘Geneesmiddelen voor Geavanceerde Therapie (ATMP’s) in Nederland: Veldverkenning, Knelpuntanalyse en Activiteitenkaart’ (in Dutch)

1 December, 2023/by Adel Medzikovic

Article in Journal of Clinical Oncology: ‘Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed’

27 November, 2023/by Adel Medzikovic

Review article in Frontiers in Immunology: ‘Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations’

24 November, 2023/by Adel Medzikovic

Review article in IOTECH: ‘Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit’

13 October, 2023/by Adel Medzikovic